



## PRESS RELEASE

---

### ASLAN PHARMACEUTICALS OPENS CHINA OFFICE

**Singapore, 8 April 2016** – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced the opening of its office in Shanghai.

This is ASLAN's first office in China, and will complement the company's existing presence in Singapore and Taiwan. The office will be responsible for managing local clinical and manufacturing activities, and will strengthen ASLAN's ability to address the significant disease burden of tumour types more common in China, such as gastric cancer and cholangiocarcinoma.

ASLAN has been collaborating with local partners in China for manufacturing and clinical activities since 2012. The Company recently received Clinical Trial Approval and will be starting its first clinical trial for its lead drug, *varlitinib*. ASLAN was also named 'Asian Biotech of the Year' at the 2016 BioPharma Asia Awards for its unique and creative approach to drug development processes.

**Ends**

#### Media contacts

**Emma Thompson / Stephanie Tan**

Spurwing Communications

Tel: +65 9107 5559

Email: [ASLAN@spurwingcomms.com](mailto:ASLAN@spurwingcomms.com)

#### About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform which reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company's proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN's most advanced compounds are in phase 2: varlitinib (ASLAN001), a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET. [www.aslanpharma.com](http://www.aslanpharma.com)